增殖细胞核抗原在鼻咽癌中表达的定量研究

为了增加鼻咽癌的诊断和预后判定指标，应用抗增殖细胞核抗原（ｐｒｏｌｉｆｅｒａｔｉｎｇｃｅｌｎｅｃｌｅａｒａｎｔｉｇｅｎ，ＰＣＮＡ）单克隆抗体，采用免疫组化染色ＬＡＳ－ＳＰ法及图象分析技术，对８２例鼻咽鳞状细胞癌和２５例鼻咽粘膜炎症组织标本进行了定量研究，并对鼻咽癌患者５年生存率与ＰＣＮＡ表达情况进行了相关性分析。结果：①根据ＰＣＮＡ阳性细胞计算的鼻咽癌细胞增殖指数与鼻咽癌的病理分级呈明显的正相关，与患者５年生存率呈明显负相关。②图像处理检测的ＰＣＮＡ表达量与鼻咽癌的病理分级也呈明显的正相关，与５年生存率呈负相关，但泡状核细胞癌虽属低分化鳞癌却不符合上述规律。结论：ＰＣＮＡ能很好地反映鼻咽癌的增殖活性，在临床病理上具有应用前景，可作为对鼻咽癌预后判定及指导临床治疗的指标     

增殖细胞核抗原及Bcl-2蛋白在鼻咽癌中的表达

目的:探讨鼻咽癌组织中增殖细胞核抗原(PCNA)、Bcl-2表达情况及与主要临床指标间的关系。方法:以免疫组化检测鼻咽活检组织中PCNA、Bcl-2蛋白表达,并比较与分析两者和鼻咽癌临床分期及颈淋巴结转移的关系。结果:鼻咽部慢性炎性组织中Bcl-2阳性率为9.5％,明显低于鼻咽癌组织中的阳性率(83.1％)(P<0.01)。PCNA、Bcl-2在鼻咽癌中的表达呈明显负相关(r_s=-0.41,P<0.01)。随着临床分期的增高,PCNA增殖指数(PI)分级有增高的趋势,鼻咽癌伴颈淋巴结转移组中PI之Ⅰ级所占比例,较无颈淋巴结转移组下降,而Ⅱ、Ⅲ、Ⅳ级所占比例增加,但无统计学意义。结论:PCNA PI可反映鼻咽癌的增殖状况,可能与预后相关,Bcl-2蛋白可作为鼻咽癌较好的肿瘤标记物,在鼻咽癌的发生上可能起重要作用。     

增殖细胞核抗原和p53基因在鼻咽癌中的表达及相关性研究

目的:通过免疫组织化学方法检测鼻咽癌(NPC)患者增殖细胞核抗原(PCNA)、p53基因表达,分析其与主要临床指标间的关系。方法:免疫组织化学检测鼻咽活检组织中PCNA、p53蛋白表达,并比较与分析两者和NPC临床分期及颈淋巴结转移的关系。结果:鼻咽部慢性炎性组织中p53阳性率为9.5%,明显低于NPC组织中的阳性率(76.3%)(P<0.01)。NPC伴颈淋巴结转移组p53阳性率(90.9%)明显高于无颈淋巴结转移组(57.7%)(P<0.01),临床Ⅱ、Ⅲ和Ⅳ期p53阳性率(分别为93.3%、80.0%和100.0%)均明显高于临床Ⅰ期(40.0%)(均P<0.01),且表达强度有增加的趋势。随着临床分期的增高,PCNA增殖指数(PI)分级有增高的趋势,NPC伴颈淋巴结转移组中PCNAPI之Ⅰ级所占比例较无颈淋巴结转移组下降,而Ⅱ、Ⅲ、Ⅳ级所占比例增加,但无统计学意义,NPC组织中PCNA表达与p53表达显著相关(P<0.01)。结论:p53蛋白可作为NPC较好的肿瘤标记物,p53阳性的NPC患者较易发生颈淋巴结转移,随着NPC病程的发展,p53表达率及表达强度均增加,PCNAPI可反映NPC的增殖状况,可能与预后相关。     

增殖细胞核抗原表达及在头颈肿瘤研究中的应用

增殖细胞核抗原（ｐｒｏｌｉｆｅｒａｔｉｎｇｃｅｌｌｎｕｃｌｅａｒａｎｔｉｇｅｎ，ＰＣＮＡ）近年来广泛应用于评价肿瘤细胞增殖状态，本介绍了ＰＣＮＡ的生物特性，评价细胞增殖状态的价值及在头颈肿瘤研究中的应用。     

增殖细胞核抗原（PCNA）,DNA含量及细胞核形态参数测定在鼻咽…

应用增殖细胞核抗原单克隆抗体ＰＣ１０免疫组化法，ＤＮＡ含量及细胞核形态图像分析法，对５８例鼻咽癌进行检测。结果显示，三种方法的检测结果具有较好的一致性，其中肿瘤细胞的ＤＮＡ指数和ＤＮＡ倍体分布最具有价值。结果表明，检测肿瘤细胞增殖活性对于判断鼻咽癌恶性变及估计患者的预后具有重要意义。     

喉癌组织中增殖细胞核抗原的表达及意义

喉癌组织中增殖细胞核抗原的表达及意义季文樾，关超，费声重增殖细胞核抗原（ＰｒｏｌｉｆｅｒａｔｉｎｇＣｅｌｌＮｕ－ｃｌｅａｒＡｎｔｉｇｅｎ，ＰＣＮＡ）是近年新兴的原位检测增殖细胞活检的免疫化学探针。我们用抗ＰＣＮＡ的单抗和免疫组化技术，对喉鳞癌作了研究...     

增殖细胞核抗原在鼻息肉组织中的表达

目的研究增殖细胞核抗原(proliferating cell neuclear antigen,PCNA)在鼻息肉组织中的表达,探讨鼻息肉中细胞增殖的病理解剖学基础,以及细胞增殖与鼻息肉发病之间的关系,为改进鼻息肉的诊断与治疗提供理论依据.方法用免疫组化法测定35例鼻息肉组织和17例正常下鼻甲组织中PCNA的表达.对PCNA 阳性细胞的类型、分布特点进行分析.以期发现鼻息肉中细胞增殖活跃与细胞类型及分布之间的关系.结果PCNA在鼻息肉组织中的表达明显高于正常对照组,差异有显著性(P＜0.05).PCNA阳性细胞主要集中于鼻息肉的上皮细胞和囊性扩张的腺体细胞中.结论鼻息肉中细胞增殖活性较正常明显提高,尤其是上皮细胞、腺体细胞和组织中浸润的炎性细胞.细胞增殖活跃在鼻息肉的形成和复发中起重要作用.     

晚期喉癌边缘DNA含量和增殖细胞核抗原表达

目的 探讨晚期喉癌边缘ＤＮＡ含量和增殖细胞核抗原（ＰＣＮＡ）表达与喉癌手术预后的关系。方法 通过ＰＣＮＡ表达和ＤＮＡ含量检测，对３４例晚期喉癌边缘进行观察。结果 肿瘤边缘１．０、０．５、０ｃｍ处粘膜，ＰＣＮＡ指数分别为８．６２％，１７．７６％和５０．３２％。ＤＮＡ指数分别为０．９８、１．０８２和１．４３６。统计学分析１．０、０．５ｃｍ处粘膜０ｃｍ处粘膜差异有显著性（Ｐ〈０．０１）。结论 中、重度非     

晚期喉癌边缘DNA含量和增殖细胞核抗原表达

目的探讨晚期喉癌边缘ＤＮＡ含量和增殖细胞核抗原（ＰＣＮＡ）表达与喉癌手术预后的关系。方法通过ＰＣＮＡ表达和ＤＮＡ含量检测，对３４例晚期喉癌边缘进行观察。结果肿瘤边缘１．０、０．５、０ｃｍ处粘膜，ＰＣＮＡ指数分别为８．６２％、１７．７６％和５０．３２％。ＤＮＡ指数分别为０．９８、１．０８２和１．４３６。统计学分析，１．０、０．５ｃｍ处粘膜与０ｃｍ处粘膜差异有显著性（Ｐ＜０．０１）。结论中、重度非典型增生的上皮在分裂，增殖等生物学行为方面已与轻度非典型增生和单纯性增生的上皮细胞不同，手术切缘应在中度非典型性增生的粘膜上皮以外，即０．５ｃｍ以外。     

EB病毒核抗原1对鼻咽癌细胞增殖及细胞周期的影响

目的 研究EB病毒核抗原1(Epstein-Barr virus nuclear antigen 1,EBNA1)对人鼻咽癌细胞增殖及细胞周期的影响.方法 构建特异性的短发夹RNA(short hairpin RNA,shRNA)EBNA1慢病毒干扰载体,包装慢病毒后感染过表达EBNA1的鼻咽癌细胞C666-EBNA1(简写为CE).应用四甲基偶氮唑蓝法(MTT)和细胞计数法检测细胞增殖状态,流式细胞术、荧光定量PCR及蛋白免疫印迹法检测细胞周期及相关调控因子变化.结果 成功构建含shRNA EBNA1的重组慢病毒,其感染可显著下调CE细胞中EBNA1表达.细胞计数和MTT均证明CE-shRNA细胞的增殖能力较CE-对照组显著下降(P值均＜0.05).细胞周期提示干扰EBNA1后CE细胞G0-G1期比例由(62.43±6.62)%升高到(89.66±0.64)%,两者比较差异有统计学意义(t=-7.091,P=0.002),S期比例由(34.93±7.36)%下降为(7.82±2.44)%,两者比较差异有统计学意义(t=6.095,P=0.004),G2-M期无明显变化(t=0.090,P=0.933).抑制EBNA1后,c-myc、CDK4、CDK6、pRb的mRNA水平分别下调65.60%、34.06%、41.05%、55.29%.蛋白免疫印迹法证实抑制EBNA1后4种蛋白的表达亦下调.结论 沉默EBNA1基因可抑制鼻咽癌细胞增殖,其机制之一可能是通过影响c-myc、CDK4、CDK6、pRb等基因的表达使鼻咽癌细胞阻滞于G0-G1期.     

Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma

PURPOSE: To assess the prognostic significance of p53 protein and proliferating cell nuclear antigen (PCNA) expression in nasopharyngeal carcinoma. MATERIALS AND METHODS: This study included 79 patients who had received treatment and regular follow-up for at least 5 years at a single institute. We used immunohistochemistry staining to assess p53 protein expression and PCNA labeling index (LI). Analyses were conducted on the association between each of the 2 biomarkers and pathological subtypes, TNM stage, the presence of locoregional recurrence, and 5-year survival rate. RESULTS: p53 protein nuclear staining was positive in 49 patients (62%). The mean PCNA LI was 55.6%, ranging from 3.35% to 92.9%. High PCNA LI (>55.6%) might contribute to higher 5-year survival rate, but it did not reach statistical significance (P = .09). Positive p53 protein staining and low PCNA LI were associated with the presence of locoregional recurrence. No statistical significance was found between p53 protein expression and PCNA LI and pathological subtypes and TNM stage. CONCLUSION: p53 protein and PCNA LI were not an ideal prognostic indicator in predicting 5-year survival rate in nasopharyngeal carcinoma. Future work will direct toward searching for other potential biomarkers with the hope to reinforce prediction of prognosis.     

血清组织多肽抗原在鼻咽癌中的表达

目的评价组织多肽抗原(TPA)在鼻咽癌诊断和监测中的临床价值。方法鼻咽癌病人28例,健康对照组10例,应用酶联免疫吸附试验(ELISA)检测TPA、EAIgA、VCAIgA三项指标并比较分析其检测结果。结果鼻咽癌组三项指标均明显高于健康对照组(P<0.05)。TPA与鼻咽癌分期、淋巴结转移和远处转移有关,病人经放射治疗后TPA值下降,TPA值一定程度上可以反映鼻咽癌转归。结论TPA和EAIgA、VCAIgA联合应用对鼻咽癌的诊治有一定价值。     

The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma

CONCLUSION: p53 protein and proliferating cell nuclear antigen (PCNA) were not ideal prognostic indicators in advanced nasopharyngeal carcinoma (NPC). Further investigation in searching for other potential biomarkers is needed to enhance the prediction of treatment outcome. OBJECTIVE: To assess the prognostic significance of p53 protein and PCNA expression in patients with advanced NPC. PATIENTS AND METHODS: This study included 46 patients with advanced NPC who had received treatment and regular follow-up for at least 5 years. We used immunohistochemistry (IHC) staining to assess p53 protein expression and PCNA labeling index, and correlate them with pathological subtypes, TNM stage, the presence of locoregional recurrence, and 5-year survival rate. RESULTS: p53 nuclear staining was positive in 32 patients (69.6%). All cases had positive PCNA nuclear staining with labeling index (LI) ranging from 6.5% to 92.9% (mean 53.4%). Only advanced T stage was found to be associated with high PCNA LI. Overexpression of p53 and PCNA LI had no impact on 5-year survival in this study group.     

鼻咽癌中表皮生长因子受体、C-erbB-2表达及其与细胞增殖的关系

目的:研究鼻咽癌组织中EGFR、C-erbB-2表达特点及其与肿瘤细胞增殖状态的关系.方法:应用免疫组织化学检测鼻咽部32例癌组织、11例慢性炎症黏膜组织中EGFR和C-erbB-2表达情况,同时计数肿瘤细胞PCNA增殖指数.结果:①鼻咽癌组织中EGFR、C-erbB-2蛋白表达阳性率和PCNA增殖指数分别为65.6%...     

Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma

CYFRA 21-1 is a newly developed tumor marker that is especially useful for detecting squamous cell carcinoma (SCC) of the lung. Squamous cell carcinoma antigen is a proven tumor marker that is especially useful for detecting SCC of the cervix. Our aim in this study was to compare the clinical value of CYFRA 21-1 and SCC antigen in the detection of nasopharyngeal carcinoma (NPC). Serum levels of CYFRA 21-1 and SCC antigen were measured in 80 untreated NPC patients and 77 healthy controls. The cutoff values of CYFRA 21-1 and SCC antigen, determined at the 95th percentile of the 77 healthy controls, were 2.48 ng/mL and 1.49 ng/mL, respectively. The results revealed that the mean serum value of only CYFRA 21-1 was significantly higher in the 80 NPC patients than in the 77 healthy controls, and the detection sensitivity of CYFRA 21-1 for NPC was significantly higher than that of SCC antigen. In conclusion, our results suggest that CYFRA 21-1 is a better tumor marker than SCC antigen for detection of NPC.